KRTAP9-2

Across TCGA pan-cancer cohorts, KRTAP9-2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated KRTAP9-2 data layer compared with 2 for mutation status.

The strongest signal is observed in small cell lung cancer (SCLC), where higher KRTAP9-2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP9-2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SCLC, SKCM, and BLCA are the cancer types where KRTAP9-2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Tertile	II,III,IV	0.164	0.819	<.001	72	view →
SKCM	OS	Quartile	II,III,IV	0.198	0.387	.001	53	view →
BLCA	DFS	Tertile	IV	0.759	0.175	.005	42	view →
LAML	DFS	Tertile	All	0.026	0.572	<.001	36	view →
HNSC	OS	Tertile	IV	0.200	0.648	.007	36	view →
LUAD	DFS	Tertile	II,III,IV	0.545	0.689	.024	15	view →
READ	DFS	Tertile	IV	0.409	0.656	.018	9	view →
LGG	OS	Tertile	All	0.156	0.460	.048	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

KRTAP9-2–SCLC (OS)

Open the SCLC breakdown →